SCHEMBL24809790

SCHEMBL24809790

COc1nc(C2CCCC2)cn1C(=O)NC1CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
GFER P55789 1/20 0.38
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
POLB P06746 1/20 0.35
TTK P33981 2/20 0.35
CNR2 P34972 2/20 0.35
CHRM4 P08173 1/20 0.35
ALDH1A1 P00352 2/20 0.35
RAB9A P51151 3/20 0.34
EPHX2 P34913 2/20 0.34
NPC1 O15118 2/20 0.34
BCHE P06276 1/20 0.34
EPHX1 P07099 1/20 0.34
P2RX1 P51575 1/20 0.34
P2RX3 P56373 1/20 0.34
P2RX4 Q99571 1/20 0.34
P2RX7 Q99572 1/20 0.34
TSHR P16473 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24810569 0.96 SMN1; SMN2 (0.42) MAPTSMN1; SMN2GFERMEN1KMT2A
SCHEMBL24809766 0.95 BCHE (0.34) MAPTSMN1; SMN2GFERPOLBTTK
SCHEMBL24809776 0.84 HPGDS (0.35) SMN1; SMN2KMT2AMAPK1
SCHEMBL24810730 0.84 SMN1; SMN2 (0.37) MAPTSMN1; SMN2GFERMEN1KMT2A
SCHEMBL24809411 0.81 CHRM4 (0.40) MAPTSMN1; SMN2GFERPOLBCHRM4
SCHEMBL24810688 0.80 PDCD1LG2 (0.36) MAPTSMN1; SMN2GFERPOLBCNR2
SCHEMBL29786262 0.80 CNR2 (0.37) CNR2RAB9ANPC1
SCHEMBL24810647 0.78 ALDH1A1 (0.38) MAPTSMN1; SMN2MEN1KMT2ATTK
SCHEMBL24810656 0.77 HPGDS (0.36) MAPTSMN1; SMN2GFERKMT2APOLB
SCHEMBL24810590 0.77 KLK7 (0.44) MAPTSMN1; SMN2MEN1KMT2ATTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220411388-A1 SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL R&D INVEST S A (PT) 2022-12-29 US disclosed
US-20220411388-A1 SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL R&D INVEST S A (PT) 2022-12-29 US disclosed
EP-4031531-A1 SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS Bial-R&D Investments, S.A. (PT) 2022-07-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220411388-A1 SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GBA1, GAA, CLN6 MAPT 217/4885SMN1; SMN2 79/4885GFER 4106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.